Alnylam Pharmaceuticals / Project Ouisa
About the project
In 2016, Alnylam embarked upon the biggest stage in their “Alnylam 2020” initiative – the design and construction of a new drug substance manufacturing and cGMP warehouse facility. After an extensive search, the 12-acre site in Norton, MA was selected for a ground up, 200,000 SF, 3-story facility which would house multiple production lines, GMP warehouse, as well as all associated office and amenity spaces. This state of the art, flagship facility will produce a new class of innovative medicines licensed for both US and EU markets and will bring over 300 jobs to the area.
As owner’s representative, Hereva worked closely with Alnylam on the site selection. Once the design team was selected, Hereva took a leadership role in managing the programming, design and engineering of the facility, as well as in assisting with the development and environmental permitting required for the project. The hiring of the CM marked another milestone in the project. Hereva continues to provide oversight of the construction manager, as well as coordination with facilities and operations on all aspects of this complex project, and providing project communications to the Alnylam team.
The project will complete the steel structure in February 2017 and is on track for operational start up in 2018.
About the Client
The discovery of RNAi has been heralded as a major scientific breakthrough that happens only once every decade or so, and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today.
Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life threatening diseases with limited treatment options for patients and their care givers.
For more information about this project: